🇺🇸 Phytonadione (Vitamin K1) in United States

13 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 13

Most-reported reactions

1. Bacteraemia — 2 reports (15.38%)
2. Hepatic Failure — 2 reports (15.38%)
3. Sepsis — 2 reports (15.38%)
4. Acute Kidney Injury — 1 report (7.69%)
5. Blood Creatinine Increased — 1 report (7.69%)
6. Blood Fibrinogen Decreased — 1 report (7.69%)
7. Blood Urea Increased — 1 report (7.69%)
8. Fall — 1 report (7.69%)
9. Hepatitis Fulminant — 1 report (7.69%)
10. Hepatorenal Syndrome — 1 report (7.69%)

Source database →

Frequently asked questions

Is Phytonadione (Vitamin K1) approved in United States?

Phytonadione (Vitamin K1) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Phytonadione (Vitamin K1) in United States?

St. Joseph's Healthcare Hamilton is the originator. The local marketing authorisation holder may differ — check the official source linked above.